Pulses are racing!

Posted:
15
September 2004

Excitement is mounting at Richmond Pharmacology as we approach the QTc workshop to be held on 29th September 2004 at St George's Hospital Medical School. The workshop has received much interest and is expected to be a huge success.Richmond Pharmacology has invited main representatives from the top pharmaceutical companies to attend a workshop where world-leading experts in cardiology from St George's Hospital Medical School and also the Medicines and Healthcare Products Regulatory Authority (MHRA) will speak on a range of QTc topics.Studies focussing on the QT interval have become of increased importance recently. A number of drugs have been withdrawn from the market as a result of their capacity to cause potentially fatal arrhythmias associated with the prolongation of the QT interval. Factors influencing the QT interval, regulatory aspects of drug induced QT interval prolongation, correcting or controlling the QT interval, and the definitive QT study will all be discussed, among other topics, at the workshop hosted by Richmond Pharmacology.To find more information on Richmond Pharmacology's QTc capabilities, or for further information on the QTc workshop, follow the link to our QTc studies page.It is not too late to register, please see the workshop page for further information. The QTc Studies page provides up to date information on the services offered by RPL in this area of expertise.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more